An ad hoc committee of the National Academies of Sciences, Engineering, and Medicine will examine the science, standards, regulation, and application of 222 nm germicidal ultraviolet energy, also called “far UV,” to inform clinical trials of far UV for preventing or reducing the transmission of respiratory infections indoors, including in workplaces. Specifically, the committee will examine:

• The appropriateness of conducting one or more robust clinical trials to safely determine the effectiveness of far UV at reducing indoor transmission of respiratory infections between persons.
• The efficacy and safety criteria that would need to be met for robust clinical trials to be conducted and the setting(s) in which these trials should occur to optimize knowledge gained as rapidly as possible.
• Other considerations for the conduct of clinical trials on far UV as appropriate.

The committee will develop a report with its findings, conclusions, and recommendations on the appropriateness, timing, and conduct of clinical trials of far UV.